phrykt

Definium Therapeutics, Inc. (DFTX): who owns it and who trades it

As of Nov 16, 2026, DFTX insiders reported 17 open-market sales worth $7M and no purchases in the last 12 months, with 33% of the sale value made under pre-set 10b5-1 plans. The largest seller was Robert Barrow (CEO), with $4M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Definium Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DFTX

359 funds and institutions reported DFTX shares worth $5.5B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 10.3%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.10.3%
Avoro Capital Advisors LLC6.6%
Driehaus Capital Management LLC6.3%
California State Teachers Retirement System5.5%
Jupiter Topco LLC5.1%
Capital World Investors4.9%
FMR LLC (Fidelity)4.4%
T. Rowe Price Associates4.3%
Geode Capital Management, LLC3.3%
State Street Corp2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.11.23M10.30%$528M+32%
Avoro Capital Advisors LLC7.19M6.59%$338M+44%
Driehaus Capital Management LLC6.85M6.28%$322M+16%
California State Teachers Retirement System6.04M5.54%$128M–
Jupiter Topco LLC5.62M5.15%$264M–
Capital World Investors5.37M4.92%$252M–
FMR LLC (Fidelity)4.75M4.36%$224M+163%
T. Rowe Price Associates4.65M4.27%$219M+6546%
Geode Capital Management, LLC3.64M3.34%$171M+46%
State Street Corp3.07M2.81%$144M+24%
Capital International Investors2.96M2.72%$139M–
Octagon Capital Advisors LP2.95M2.70%$139M+21%
Wellington Management Group LLP2.95M2.70%$139M+126%
Deep Track Capital, LP2.75M2.52%$129M-8%
Commodore Capital LP2.00M1.83%$94.1MNo change
Alliancebernstein L.P.1.80M1.65%$34.1M+1866%
Goldman Sachs Group Inc1.80M1.65%$84.7M+7%
Citadel Advisors LLC1.69M1.55%$79.4M+27%
Vanguard Portfolio Management LLC1.65M1.51%$77.5M+89%
Ra Capital Management, L.P.1.50M1.38%$70.6M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DFTX insiders reported $0 of open-market purchases and $7M of sales. 33% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$7M
17 trades, 5 people
Sales under a 10b5-1 plan
33%
Share of sale value
Latest trade
Sep 25, 2026
Filed Sep 29, 2026

Purchases and sales by month

$3M$3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 25, 2026Daniel KarlinDirectorSale plan10,853$36.57$397KForm 4
Sep 25, 2026Robert BarrowCEOSale plan31,550$36.57$1.2MForm 4
Sep 25, 2026Matthew T. WileyChief Commercial OfficerSale plan3,097$36.57$113KForm 4
Sep 25, 2026Mark SullivanChief Legal OfficerSale plan14,051$36.57$514KForm 4
Sep 25, 2026Brandi RobertsCFOSale plan3,377$36.57$123KForm 4
Sep 3, 2026Robert BarrowCEOSale19,023$37.94$722KForm 4
Jun 25, 2026Mark SullivanChief Legal OfficerSale13,008$45.03$586KForm 4
Jun 25, 2026Daniel KarlinChief Medical OfficerSale10,035$45.03$452KForm 4
Jun 25, 2026Brandi RobertsCFOSale3,013$45.03$136KForm 4
Jun 25, 2026Robert BarrowCEOSale29,208$45.03$1.3MForm 4
Jun 25, 2026Matthew T. WileyChief Commercial OfficerSale2,867$45.03$129KForm 4
Mar 25, 2026Daniel KarlinChief Medical OfficerSale8,018$18.47$148KForm 4
Mar 25, 2026Mark SullivanChief Legal OfficerSale10,702$18.47$198KForm 4
Mar 25, 2026Robert BarrowCEOSale24,431$18.47$451KForm 4
Dec 26, 2025Daniel KarlinChief Medical OfficerSale5,600$13.15$73.6KForm 4
Dec 26, 2025Robert BarrowCEOSale25,791$13.15$339KForm 4
Dec 26, 2025Mark SullivanChief Legal OfficerSale11,276$13.15$148KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Robert BarrowChief Executive Officer, Director–$4MSep 25, 2026
Mark SullivanChief Legal Officer–$1.4MSep 25, 2026
Daniel KarlinChief Medical Officer–$1.1MSep 25, 2026
Brandi RobertsChief Financial Officer–$259KSep 25, 2026
Matthew T. WileyChief Commercial Officer–$242KSep 25, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DFTX short interest

Moderate short interest. 7.2% of DFTX shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 4%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.61M DFTX shares were sold short, 7.2% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 1.66M shares, buying them all back would take about 5.8 trading days (days to cover).

Shares short, % of all shares

7.16%May 15Oct 3014.3%

Days to cover

5.8May 15Oct 307.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.61M7.16%-4%1.66M5.8
Oct 15, 202610.04M7.48%-11%2.06M4.9
Sep 30, 202611.34M8.44%-4%2.32M4.9
Sep 15, 202611.79M8.77%+20%2.27M5.2
Aug 31, 20269.84M7.32%+10%1.75M5.6
Aug 14, 20268.97M6.68%-17%2.66M3.4
Jul 31, 202610.74M7.99%+1%1.63M6.6
Jul 15, 202610.64M9.76%-27%2.27M4.7
Jun 30, 202614.52M13.31%+36%7.07M2.0
Jun 15, 202610.64M9.75%+13%2.39M4.4
May 29, 20269.43M8.64%+2%1.81M5.2
May 15, 20269.25M8.48%-1%1.40M6.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Definium Therapeutics company events

Definium Therapeutics filed 15 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Sep 14, 2026AnnouncementThe Company posted a presentation discussing the Panorama topline data to its website. Filing
  3. Sep 8, 2026AnnouncementDefinium Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted breakthrough designation to the Company’s DT120 ODT program for the treatment of major depressive disorder. Filing
  4. Aug 12, 2026AnnouncementThe information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by… Filing
  5. Aug 6, 2026ResultsReleased financial results. Filing
  6. Jun 24, 2026AgreementDefinium Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, and BofA Securities, Inc., as representatives of the several underwriters named therein, in connection with an underwritten public offering of 20,588,236 common… Filing
  7. Jun 22, 2026AnnouncementThe Company posted a presentation discussing the Emerge topline data on its website. Filing
  8. Jun 12, 2026LeadershipApproval of Amendment to the Definium Therapeutics, Inc. 2025 Equity Incentive Plan As described in Item 5.07 below, on June 11, 2026, Definium Therapeutics, Inc. held its 2026 Annual General and Special Meeting of Shareholders. Filing
  9. May 19, 2026AnnouncementDefinium Therapeutics, Inc. posted an updated corporate presentation on its website. Filing
  10. May 12, 2026AnnouncementDefinium Therapeutics, Inc. issued a press release announcing the first patient dosed in the Company's Phase 3 Ascend study of DT120 Orally Disintegrating Tablet in Major Depressive Disorder. Filing
  11. May 7, 2026ResultsReleased financial results. Filing
  12. Apr 22, 2026AnnouncementDefinium Therapeutics, Inc. issued a press release announcing clinical and commercial updates presented at the Company's Investor and Analyst Day. Filing
  13. Feb 26, 2026ResultsReleased financial results. Filing
  14. Jan 29, 2026LeadershipThe Board of Directors of Definium Therapeutics, Inc., upon recommendation of the Nominating and Governance Committee of the Board, increased the size of the Board from six (6) to seven (7) directors and appointed Roger Adsett to fill the vacancy on the Board, effective January 29, 2026, with a… Filing
  15. Jan 12, 2026AnnouncementThe Company issued a press release announcing the rebranding. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Definium Therapeutics financials

Famous investors that hold DFTX

2 of the 50 well-known investors we track reported holding DFTX in their latest 13F filing. The largest position is Israel Englander's, worth $1.5M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 202640,492$1.5M0.0%-85%
Paul Tudor Jones · Tudor Investment CorpQ3 202617,655$672K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named DFTX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G5.4%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G5.4%
Nov 13, 2026Capital World Investors13G6.1%
Nov 13, 2026Capital World Investors13G6.1%
Nov 5, 2026FMR LLC13G6.5%
Nov 5, 2026FMR LLC13G6.5%

Questions about Definium Therapeutics, Inc. (DFTX) stock

Who owns the most DFTX stock?

The largest reported owner of Definium Therapeutics, Inc. (DFTX) is BlackRock, Inc., with 10.3% of the company. In total, 359 funds and institutions reported holding DFTX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are DFTX insiders buying or selling?

In the last 12 months, DFTX insiders reported no open-market purchases and 17 sales worth $7M. The latest trade was on Sep 25, 2026. See every trade.

What is the short interest in DFTX?

As of Oct 30, 2026, 9.61M DFTX shares were sold short, 7.2% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 1.66M shares, buying them all back would take about 5.8 trading days (days to cover). See the history.

Which famous investors hold DFTX?

2 of the 50 well-known investors we track reported DFTX in their latest 13F filing, including Israel Englander, Paul Tudor Jones. The largest position is worth $1.5M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.